Study on Shengxuening Tablets combined with roxadustat in treatment of anemia in patients on maintenance hemodialysis
Objective To observe the clinical effect of Shengxuening Tablets combined with roxadustat in treatment of maintenance hemodialysis anemia(MHDA).Methods A total of 120 MHDA patients were randomly divided into study group and control group,with 60 cases in each group.Control group was treated with roxadustat,and study group was treated with Shengxuening Tablets on the basis of control group.The clinical efficacy,anemia indicators[hemoglobin(Hb),hematocrit(Hct),red blood cell count(RBC)],blood lipid indicators[total cholesterol(TC),low-density lipoprotein cholesterol lipid(LDL)],microinflammation indicators[C-reactive protein(CRP),interleukin-6(IL-6)],iron metabolism indicators[serum iron(SI),transferrin saturation(TSAT)],renal function indicators[serum urea nitrogen(BUN),serum creatinine(Scr),24 h Urine protein excretion rate(UPE)]and TCM syndrome score(main symptom,secondary symptom,total score)of the two groups were compared.Results After treatment,the total effective rate of study group was higher than that of the control group(P＜0.05);the levels of Hb,Hct,RBC,SI,and TSAT in both groups were higher than those before treatment,and were higher in study group than those in control group(P＜0.05);the levels of TC,LDL,CRP,IL-6,BUN,Scr,and 24 hUPE in both groups were lower than those before treatment,and were lower in study group than control group(P＜0.05).Conclusion Shengxuening Tablets combined with roxadustat can correct iron deficiency,promote hematopoiesis,reduce blood lipids,improve renal function,and improve TCM syndrome and micro-inflammatory status in treatment of MHDA.
NETL
NSTL
万方数据
